Annual Changes to the NASDAQ Biotechnology Index
The following 21 securities will be added to the Index:
Exchange | SYMBOL | COMPANY |
Nasdaq | AIMT | Aimmune Therapeutics, Inc. |
Nasdaq | ARLZ | Aralez Pharmaceuticals Inc. |
Nasdaq | AVXS | AveXis, Inc. |
Nasdaq | BGNE | BeiGene, Ltd. |
Nasdaq | BOLD | Audentes Therapeutics |
Nasdaq | CLCD | CoLucid Pharmaceuticals |
Nasdaq | CLSD | Clearside Biomedical, Inc. |
Nasdaq | CYTK | Cytokinetics, Incorporated |
Nasdaq | EDIT | Editas Medicine, Inc. |
Nasdaq | GBT | Global Blood Therapeutics |
Nasdaq | ITCI | Intra-Cellular Therapies |
Nasdaq | LOXO | Loxo Oncology, Inc. |
Nasdaq | MNOV | Medicinova Inc |
Nasdaq | NERV | Minerva Neurosciences |
Nasdaq | NH | NantHealth, Inc. |
Nasdaq | NTLA | Intellia Therapeutics, Inc. |
Nasdaq | NVCR | NovoCure Limited |
Nasdaq | ONVO | Organovo Holdings Inc |
Nasdaq | OPK | OPKO Health, Inc. |
Nasdaq | PRTK | Paratek Pharmaceuticals, Inc. |
Nasdaq | RGNX | REGENXBIO Inc. |
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 37 securities will be removed from the Index:
Exchange | SYMBOL | COMPANY |
Nasdaq | ADHD | Alcobra Ltd. |
Nasdaq | ADVM | Adverum Biotechnologies, Inc. |
Nasdaq | AFMD | Affimed N.V. |
Nasdaq | AGTC | Applied Genetic Technologies Corporation |
Nasdaq | ANTH | Anthera Pharmaceuticals, Inc. |
Nasdaq | CARA | Cara Therapeutics, Inc. |
Nasdaq | CASC | Cascadian Therapeutics, Inc. |
Nasdaq | CHMA | Chiasma, Inc. |
Nasdaq | CMRX | Chimerix, Inc. |
Nasdaq | CNCE | Concert Pharmaceuticals, Inc. |
Nasdaq | CXRX | Concordia International Corp. |
Nasdaq | DNAI | ProNAi Therapeutics, Inc. |
Nasdaq | DRNA | Dicerna Pharmaceuticals, Inc. |
Nasdaq | DRRX | DURECT Corporation |
Nasdaq | ECYT | Endocyte, Inc. |
Nasdaq | EGLT | Egalet Corporation |
Nasdaq | FLKS | Flex Pharma, Inc. |
Nasdaq | IMDZ | Immune Design Corp. |
Nasdaq | IMGN | ImmunoGen, Inc. |
Nasdaq | INFI | Infinity Pharmaceuticals, Inc. |
Nasdaq | ITEK | Inotek Pharmaceuticals Corporation |
Nasdaq | KMPH | KemPharm, Inc. |
Nasdaq | LIFE | aTyr Pharma, Inc. |
Nasdaq | MNKD | MannKind Corporation |
Nasdaq | NDRM | NeuroDerm Ltd. |
Nasdaq | NEOS | Neos Therapeutics, Inc. |
Nasdaq | OCUL | Ocular Therapeutix, Inc. |
Nasdaq | OREX | Orexigen Therapeutics, Inc. |
Nasdaq | OSIR | Osiris Therapeutics, Inc. |
Nasdaq | OVAS | OvaScience Inc. |
Nasdaq | QURE | uniQure N.V. |
Nasdaq | RGLS | Regulus Therapeutics Inc. |
Nasdaq | SCLN | SciClone Pharmaceuticals, Inc. |
Nasdaq | TKAI | Tokai Pharmaceuticals, Inc. |
Nasdaq | TTPH | Tetraphase Pharmaceuticals, Inc. |
Nasdaq | VTL | Vital Therapies, Inc. |
Nasdaq | ZFGN | Zafgen, Inc. |
About Nasdaq
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an
overall investment strategy. Neither
NDAQG
Media Contacts:Source: NASDAQ, Inc.Peter Gau , Nasdaq +1.212.231.5475 Issuer & Investor Contact:Natasha Selzer , Nasdaq +1.301.978.8623
News Provided by Acquire Media